Company

Nvelop Therapeutics, Inc.

Nvelop Therapeutics develops genetic medicines and delivery platforms for diseases that have been difficult to treat.

About

Based in Massachusetts, Nvelop Therapeutics developed DLVR-X and DLVR-M, non-viral delivery platforms designed for tissue-specific delivery and in vivo gene editing. The company was founded in 2022 by Keith Joung and David Liu. In December 2024, it merged with Chroma Medicine to form nChroma Bio. It was at the Seed stage.

1Funding rounds

6Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in